-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
immunotherapy
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
Mario Lacouture, MD, is director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center and specializes in the dermatologic side effects of cancer treatment. He is the founder of the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary program bringing together patient care, education, and research, and is…
-
Therapeutic Vaccine Development in Lung Cancer: Update and Recent Advances
Most cancer immunotherapies currently in development aim to stimulate antitumor T-cell responses either by adoptive transfer of in vitro expanded native or genetically modified T lymphocytes targeting malignant cells,1 ,2 administration of neutralizing monoclonal antibodies (mAb) specific to T-cell inhibitory receptors, such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed death-1 (PD-1),3 ,4 ,5 ,6 ,7…
-
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy
By Kara Nyberg, PhD Posted: June 24, 2020 Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food and Drug Administration (FDA) and Synapse, a consultancy firm, retrospectively analyzed both clinical trial data and real-world data (RWD) taken from the Advocate Aurora Health System to elucidate risk…
-
Systemic Therapy for Advanced Stage Lung Cancer During the COVID-19 Pandemic
Watch Recording IASLC faculty members from Europe, Asia and North America will discuss systemic therapies including chemotherapy, immunotherapy, and targeted therapy for advanced-stage lung cancer during the COVID-19 global pandemic. The faculty will share their experience and advice on 1) how COVID-19 impacts their patient population, 2) changes made in the management of current and…
-
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are now available in routine clinical practice for the treatment of patients with advanced or metastatic NSCLC and SCLC. Several biomarkers have been reported to predict…
-
Doctor of Nursing Practice Project Aims to Educate Non-Oncology Providers About the Management of Immunotherapy AEs
By Enza Esposito Nguyen, DNP, RN, ANP-BC Posted: February 12, 2020 Dr. Enza Esposito Nguyen Although we continue to see many immunotherapy clinical trials mature and deliver marvelous improvements in PFS and OS in lung cancer and many other malignancies, managing some of the adverse events (AEs) of immunotherapy has become a unique challenge.…
-
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC
This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on patients with poor performance status. By Valérie Gounant, MD, and Elisabeth Quoix, MD, PhD Posted: February 12, 2020 Dr. Valérie Gounant Prof. Elisabeth Quoix The advent of…
-
Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab
By Suresh Ramalingam, MD Posted: December 11, 2019 IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37(28):2518-2527. Immune checkpoint inhibition is now part of routine care for patients with…
-
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data
Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. Greg Durm, MD, is a medical oncologist at the Indiana University Simon Cancer Center and principal investigator of a phase II trial examining concurrent chemoradiation…
View ILCN Archives
Provider Resources
Popular Articles